Close Menu

NEW YORK – MDxHealth announced Monday that private equity firm MVM Partners has agreed to provide an equity investment of €12.7 million ($13.8 million) to the company.

MVM Partners will receive a subscription of nearly 20.2 million ordinary shares of MDxHealth at an issue price of €0.63 per share, a 5 percent discount to the 45-day volume weighted average price. MVM will become a 22 percent shareholder of the company after the transaction, which is expected to close on or around May 15. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.